Fibrosis–a common pathway to organ injury and failure
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
Fibrosis is a consequence of the inflammatory response. When fibrotic tissue becomes excessive, it can have diverse pathophysiological effects on a number of organ systems. The mechanisms underlying fibrosis and approaches to therapy are reviewed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hepatocyte injury, apoptosis and necrosis promote a sterile inflammatory response. This includes activation of KCs to clear necrotic debris, recruitment of lymphocytes and bone-marrow-derived monocytes, extracellular matrix (ECM) remodelling, myofibroblast activation, angiogenesis, and hepatocyte regeneration and differentiation to replace lost hepatocytes.11,31,32”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [31]
In the citing paper
“Both receptors are independently involved in regulation of cell adhesion, differentiation, proliferation of myofibroblasts and migration of both myofibroblasts and macrophages.31”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [31]
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Massagué, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3434 · Cited by 3,128
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Research works printed but not linked: 1
- TORAFIC Investigators Group, 2011, Clin Ther, 33, 1204.e3
Cited by
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
“This process was performed iteratively using only the top cell types from the previous step and the variable genes among them until only one cell type remained (for details see Methods, Supplementary Information 1 and the SingleR Github repository at https://github.com/dviraran/SingleR ).”
InfluentialRicheldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Mechanobiology of YAP and TAZ in physiology and disease
Panciera, T., Azzolin, L., Cordenonsi, M., & Piccolo, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.87 · Cited by 1,461
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033
Kidney fibrosis: from mechanisms to therapeutic medicines
Huang, R., Fu, P., & Ma, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01379-7 · Cited by 781
Spectrum of fibrotic lung diseases
Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2005230 · Cited by 736
Biomaterials: Foreign Bodies or Tuners for the Immune Response?
Mariani, E., Lisignoli, G., Borzì, R. M., & Pulsatelli, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030636 · Cited by 706
“Myofibroblasts (as suggested the “myo” prefix) share proteins of the smooth-muscle cells, whose contraction can concur to fibrotic scar formation [106].”
BackgroundCellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Muhl, L., Genové, G., Leptidis, S., Liu, J., He, L., Mocci, G., Sun, Y., Gustafsson, S., Buyandelger, B., Chivukula, I. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17740-1 · Cited by 665
IL-11 is a crucial determinant of cardiovascular fibrosis
Schafer, S., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Moreno-Moral, A., DeLaughter, D. M., Ng, B., Patone, G., Chow, K., Khin, E., et al. (2017) · Nature · doi:10.1038/nature24676 · Cited by 639
Extracellular matrix as a driver of progressive fibrosis
Herrera, J., Henke, C. A., & Bitterman, P. B. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93557 · Cited by 615
Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases
Hinz, B., & Lagares, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0324-5 · Cited by 614
Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis
Mizoguchi, F., Slowikowski, K., Wei, K., Marshall, J. L., Rao, D. A., Chang, S. K., Nguyen, H. N., Noss, E. H., Turner, J. D., Earp, B. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02892-y · Cited by 596
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
“(4) high-affinity ligand traps prevent TGF-β from binding to its receptor.”
BackgroundSelders, G. S., Fetz, A. E., Radic, M. Z., & Bowlin, G. L. (2017) · Regenerative Biomaterials · doi:10.1093/rb/rbw041 · Cited by 538
“Additionally, in many tumors, the cancer cells are responsible for none of the matrixdegrading proteins (MMPs), leaving that up to the inflammatory cells like the N2 neutrophil [34].”
BackgroundInfluentialSenescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis
Yao, C., Guan, X., Carraro, G., Parimon, T., Liu, X., Huang, G., Mulay, A., Soukiasian, H. J., David, G., Weigt, S. S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202004-1274oc · Cited by 520
Ferulic acid: A review of its pharmacology, pharmacokinetics and derivatives
Li, D., Rui, Y.-X., Guo, S.-D., Luan, F., Liu, R., & Zeng, N. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119921 · Cited by 506
The extracellular matrix as a multitasking player in disease
Theocharis, A. D., Manou, D., & Karamanos, N. K. (2019) · The FEBS Journal · doi:10.1111/febs.14818 · Cited by 511
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
“While pharmacological therapies for the complications of the metabolic syndrome are numerous, therapies for liver inflammation in NASH are just emerging, and approved therapies for liver fibrosis remain elusive (8,54,55,60-65).”
BackgroundCellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge
Piersma, B., Bank, R. A., & Boersema, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00059 · Cited by 442
The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis
Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., & Keswani, S. G. (2020) · Advances in Wound Care · doi:10.1089/wound.2019.1032 · Cited by 433
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog
Edeling, M., Ragi, G., Huang, S., Pavenstädt, H., & Susztak, K. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.54 · Cited by 430
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
A new perspective on NAFLD: Focusing on lipid droplets
Scorletti, E., & Carr, R. M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.009 · Cited by 373
Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences
Panizo, S., Martínez-Arias, L., Alonso-Montes, C., Cannata, P., Martín-Carro, B., Fernández-Martín, J. L., Naves-Díaz, M., Carrillo-López, N., & Cannata-Andía, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010408 · Cited by 372
Albumin in decompensated cirrhosis: new concepts and perspectives
Bernardi, M., Angeli, P., Claria, J., Moreau, R., Gines, P., Jalan, R., Caraceni, P., Fernandez, J., Gerbes, A. L., O'Brien, A. J., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318843 · Cited by 357
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
Pardali, E., Sanchez-Duffhues, G., Gomez-Puerto, M., & Ten Dijke, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102157 · Cited by 360
Jun, J.-I., & Lau, L. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93563 · Cited by 345
Cardiorenal Syndrome Revisited
Zannad, F., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 335
Reactive oxygen species and fibrosis: further evidence of a significant liaison
Richter, K., & Kietzmann, T. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2445-3 · Cited by 322
“Although some organ-specific aspects of fibrosis are known, fibrosis is not restricted to any particular organ and is found to occur in all organs and tumour tissues (Dvorak et al. 1984; Dvorak 1986; Kalluri and Zeisberg 2006; Rockey et al. 2015) suggesting the existence of a common pathogenetic pattern in which fibro…”
BackgroundMechanoregulation of YAP and TAZ in Cellular Homeostasis and Disease Progression
Cai, X., Wang, K.-C., & Meng, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.673599 · Cited by 304
The fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
Pathological mechanisms and therapeutic outlooks for arthrofibrosis
Usher, K. M., Zhu, S., Mavropalias, G., Carrino, J. A., Zhao, J., & Xu, J. (2019) · Bone Research · doi:10.1038/s41413-019-0047-x · Cited by 285
Tenascin-C drives persistence of organ fibrosis
Bhattacharyya, S., Wang, W., Morales-Nebreda, L., Feng, G., Wu, M., Zhou, X., Lafyatis, R., Lee, J., Hinchcliff, M., Feghali-Bostwick, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms11703 · Cited by 292
Muñoz-Durango, N., Fuentes, C., Castillo, A., González-Gómez, L., Vecchiola, A., Fardella, C., & Kalergis, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17070797 · Cited by 282
Fibrosis — A Common Pathway to Organ Injury and Failure
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1504848 · Cited by 284
Metabolic inflammation in heart failure with preserved ejection fraction
Schiattarella, G. G., Rodolico, D., & Hill, J. A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa217 · Cited by 284
Self-citationYAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 277
D'Urso, M., & Kurniawan, N. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.609653 · Cited by 280
Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases
Piera-Velazquez, S., Mendoza, F., & Jimenez, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040045 · Cited by 273
Pathogenic mechanisms of pancreatitis
Manohar, M., Verma, A. K., Venkateshaiah, S. U., Sanders, N. L., & Mishra, A. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i1.10 · Cited by 269
Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality
Sano, S., Horitani, K., Ogawa, H., Halvardson, J., Chavkin, N. W., Wang, Y., Sano, M., Mattisson, J., Hata, A., Danielsson, M., et al. (2022) · Science · doi:10.1126/science.abn3100 · Cited by 258
Rieder, F., Latella, G., Magro, F., Yuksel, E. S., Higgins, P. D. R., Di Sabatino, A., de Bruyn, J. R., Rimola, J., Brito, J., Bettenworth, D., et al. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw055 · Cited by 261
Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts
Shi, X., Young, C. D., Zhou, H., & Wang, X.-J. (2020) · Biomolecules · doi:10.3390/biom10121666 · Cited by 243
Inhibition of Hypertrophy Is a Good Therapeutic Strategy in Ventricular Pressure Overload
Schiattarella, G. G., & Hill, J. A. (2015) · Circulation · doi:10.1161/circulationaha.115.013894 · Cited by 250
Self-citationCardiac aging and heart disease in humans
Steenman, M., & Lande, G. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0255-9 · Cited by 249
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3765 · Cited by 246
“Failure of myofibroblasts to undergo apoptosis or revert to a quiescent phenotype may contribute to the excessive production, remodeling, and cross-linking of extracellular matrix (ECM) that characterizes progressive fibrotic diseases (6–8) and drives disease progression to end-organ failure and death (7).”
BackgroundGrowth and remodelling of living tissues: perspectives, challenges and opportunities
Ambrosi, D., Ben Amar, M., Cyron, C. J., DeSimone, A., Goriely, A., Humphrey, J. D., & Kuhl, E. (2019) · Journal of The Royal Society Interface · doi:10.1098/rsif.2019.0233 · Cited by 250
Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences
Richter, K., Konzack, A., Pihlajaniemi, T., Heljasvaara, R., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.015 · Cited by 238
Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease
Kai, F., Laklai, H., & Weaver, V. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.03.007 · Cited by 243
A transcriptional switch governs fibroblast activation in heart disease
Alexanian, M., Przytycki, P. F., Micheletti, R., Padmanabhan, A., Ye, L., Travers, J. G., Gonzalez-Teran, B., Silva, A. C., Duan, Q., Ranade, S. S., et al. (2021) · Nature · doi:10.1038/s41586-021-03674-1 · Cited by 238
Time to redefine endometriosis including its pro-fibrotic nature
Vigano, P., Candiani, M., Monno, A., Giacomini, E., Vercellini, P., & Somigliana, E. (2018) · Human Reproduction · doi:10.1093/humrep/dex354 · Cited by 235
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
Cartilage oligomeric matrix protein: COMPopathies and beyond
Posey, K. L., Coustry, F., & Hecht, J. T. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.023 · Cited by 221
LncRNA: Shedding light on mechanisms and opportunities in fibrosis and aging
Yang, Z., Jiang, S., Shang, J., Jiang, Y., Dai, Y., Xu, B., Yu, Y., Liang, Z., & Yang, Y. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.001 · Cited by 220
Scheibe, K., Kersten, C., Schmied, A., Vieth, M., Primbs, T., Carlé, B., Knieling, F., Claussen, J., Klimowicz, A. C., Zheng, J., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.029 · Cited by 215
Endoplasmic reticulum stress in the pathogenesis of fibrotic disease
Kropski, J. A., & Blackwell, T. S. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93560 · Cited by 206
MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives
Hasselbalch, H. C., & Bjørn, M. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/102476 · Cited by 206
Mechanisms for the transition from physiological to pathological cardiac hypertrophy
Oldfield, C. J., Duhamel, T. A., & Dhalla, N. S. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0566 · Cited by 204
Unifying mechanism for different fibrotic diseases
Wernig, G., Chen, S.-Y., Cui, L., Van Neste, C., Tsai, J. M., Kambham, N., Vogel, H., Natkunam, Y., Gilliland, D. G., Nolan, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621375114 · Cited by 206
Targeting the renin-angiotensin-aldosterone system in fibrosis
AlQudah, M., Hale, T. M., & Czubryt, M. P. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.04.005 · Cited by 191
CNS fibroblasts form a fibrotic scar in response to immune cell infiltration.
Dorrier, C. E., Aran, D., Haenelt, E. A., Sheehy, R. N., Hoi, K. K., Pintarić, L., Chen, Y., Lizama, C. O., Cautivo, K. M., Weiner, G. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00770-9 · Cited by 199
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
Therapeutic approaches to control tissue repair and fibrosis: Extracellular matrix as a game changer
Walraven, M., & Hinz, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.020 · Cited by 191
Cigarette smoking and liver diseases
Marti-Aguado, D., Clemente-Sanchez, A., & Bataller, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.016 · Cited by 190
Selman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
Hepatic macrophages: Key players in the development and progression of liver fibrosis
Cheng, D., Chai, J., Wang, H., Fu, L., Peng, S., & Ni, X. (2021) · Liver International · doi:10.1111/liv.14940 · Cited by 188
Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction
Noskovicova, N., Hinz, B., & Pakshir, P. (2021) · Cells · doi:10.3390/cells10071794 · Cited by 184
Extracellular Matrix Remodeling in Chronic Liver Disease
Ortiz, C., Schierwagen, R., Schaefer, L., Klein, S., Trepat, X., & Trebicka, J. (2021) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-021-00030-3 · Cited by 177
The WNT signaling pathways in wound healing and fibrosis
Burgy, O., & Königshoff, M. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.017 · Cited by 175
Russo, B., Brembilla, N. C., & Chizzolini, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00648 · Cited by 176
Molecular assessment of disease states in kidney transplant biopsy samples
Halloran, P. F., Famulski, K. S., & Reeve, J. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.85 · Cited by 179
TGF-β, EMT, and resistance to anti-cancer treatment
Wang, X., Eichhorn, P. J. A., & Thiery, J. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.10.004 · Cited by 170
Diabetic wound healing in soft and hard oral tissues
KO, K. I., SCULEAN, A., & GRAVES, D. T. (2021) · Translational Research · doi:10.1016/j.trsl.2021.05.001 · Cited by 173
O'Connell, P. J., Zhang, W., Menon, M. C., Yi, Z., Schröppel, B., Gallon, L., Luan, Y., Rosales, I. A., Ge, Y., Losic, B., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30826-1 · Cited by 177
The utility of liver biopsy in 2020
Khalifa, A., & Rockey, D. C. (2020) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000621 · Cited by 172
Self-citationNuclear mechanosensing drives chromatin remodelling in persistently activated fibroblasts
Walker, C. J., Crocini, C., Ramirez, D., Killaars, A. R., Grim, J. C., Aguado, B. A., Clark, K., Allen, M. A., Dowell, R. D., Leinwand, L. A., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00709-w · Cited by 172
Cardiac Fibrosis and Fibroblasts
Kurose, H. (2021) · Cells · doi:10.3390/cells10071716 · Cited by 171
Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production
Nigdelioglu, R., Hamanaka, R. B., Meliton, A. Y., O'Leary, E., Witt, L. J., Cho, T., Sun, K., Bonham, C., Wu, D., Woods, P. S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756247 · Cited by 169
Yap/Taz deletion in Gli(+) cell-derived myofibroblasts attenuates fibrosis
Liang, M., Yu, M., Xia, R., Song, K., Wang, J., Luo, J., Chen, G., & Cheng, J. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121354 · Cited by 169
Inui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Epithelial–mesenchymal transition in tissue repair and degeneration
Youssef, K. K., & Nieto, M. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00733-z · Cited by 159
Heparanase and the hallmarks of cancer
Jayatilleke, K. M., & Hulett, M. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02624-1 · Cited by 181
Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases
Yang, P., Luo, Q., Wang, X., Fang, Q., Fu, Z., Li, J. X., Lai, Y., Chen, X., Xu, X., Peng, X., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202110-2414oc · Cited by 163
Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities
Ren, L., Li, X., Duan, T., Li, Z.-H., Yang, J., Zhang, Y., Zou, L., Miao, H., & Zhao, Y. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110289 · Cited by 175
Human Fibrotic Diseases: Current Challenges in Fibrosis Research
Rosenbloom, J., Macarak, E., Piera-Velazquez, S., & Jimenez, S. A. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7113-8_1 · Cited by 158
B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease
Della‐Torre, E., Rigamonti, E., Perugino, C. A., Sain, S. B., Sun, N., Kaneko, N., Maehara, T., Rovati, L., Ponzoni, M., Milani, R., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.07.004 · Cited by 169
Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage–myofibroblast transition
Tang, P. M.-K., Zhang, Y.-Y., Xiao, J., Tang, P. C.-T., Chung, J. Y.-F., Li, J., Xue, V. W., Huang, X.-R., Chong, C. C.-N., Ng, C.-F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917663117 · Cited by 152
Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Rockey, D. C., & Friedman, S. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.065 · Cited by 156
Self-citationPharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review
Junren, C., Xiaofang, X., Huiqiong, Z., Li, G., Yanpeng, Y., Xiaoyu, C., Gao, Y., Li, Y., Zhang, Y., Fu, P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660757 · Cited by 170
Fibrosis imaging: Current concepts and future directions
Baues, M., Dasgupta, A., Ehling, J., Prakash, J., Boor, P., Tacke, F., Kiessling, F. M., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.013 · Cited by 164
Inzaugarat, M. E., Johnson, C. D., Holtmann, T. M., McGeough, M. D., Trautwein, C., Papouchado, B. G., Schwabe, R., Hoffman, H. M., Wree, A., & Feldstein, A. E. (2019) · Hepatology · doi:10.1002/hep.30252 · Cited by 148
“Fibrosis is the result of a sustained scarring response to chronic liver injury, which gradually disrupts liver architecture and causes vascular distortion, eventually leading to cirrhosis.(17) Several sources functioning as important players in LF development have been identified.”
BackgroundCleland, J. G. F., Ferreira, J. P., Mariottoni, B., Pellicori, P., Cuthbert, J. J., Verdonschot, J. A. J., Petutschnigg, J., Ahmed, F. Z., Cosmi, F., Rocca, H. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa758 · Cited by 148
Mechanisms of Lung Fibrosis Resolution
Glasser, S. W., Hagood, J. S., Wong, S. S., Taype, C. A., Madala, S. K., & Hardie, W. D. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.01.018 · Cited by 159
Mechano-therapeutics: Targeting Mechanical Signaling in Fibrosis and Tumor Stroma
Tschumperlin, D. J., & Lagares, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107575 · Cited by 141
Keloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases
Macarak, E. J., Wermuth, P. J., Rosenbloom, J., & Uitto, J. (2021) · Experimental Dermatology · doi:10.1111/exd.14243 · Cited by 139
Metadata
- Authors
- Rockey, D. C., Bell, P. D., & Hill, J. A.
- Affiliations
- Medical University of South Carolina (US)
- The University of Texas Southwestern Medical Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-19
- Volume
- 372
- Issue
- 12
- Pages
- 1138-1149
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1977437151
- Cited by
- 1,428
- References
- 118
- Citations by year
- 2026: 104 · 2025: 116 · 2024: 154 · 2023: 149 · 2022: 162 · 2021: 162 · 2020: 152 · 2019: 118 · 2018: 96 · 2017: 94 · 2016: 85 · 2015: 33
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- fibrosis, organ damage, organ failure, inflammation, fibrosis mechanisms, fibrosis treatment
- MeSH terms
- Fibrosis, Humans, Multiple Organ Failure, Transforming Growth Factor beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.